LACTB and hematologic disorder: Likewise, beta-lactam/beta-lactamase inhibitor combinations, fluoroquinolones, and macrolides were used in greater amounts among patients with hematological malignancies and lung cancer during their last month of life (Supplementary Figure 5A).